These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35090321)

  • 1. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy.
    Liu L; Zhang J; Ferguson MK; Appelbaum D; Zhang JX; Pu Y
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):16. PubMed ID: 35090321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Finkle JH; Penney BC; Pu Y
    Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new PET/CT volumetric prognostic index for non-small cell lung cancer.
    Zhang H; Wroblewski K; Jiang Y; Penney BC; Appelbaum D; Simon CA; Salgia R; Pu Y
    Lung Cancer; 2015 Jul; 89(1):43-9. PubMed ID: 25936471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
    Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
    Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
    Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
    Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic active tumour volume quantified on [
    Rocha ALG; da Conceição MAM; da Cunha Sequeira Mano FXP; Martins HC; Costa GMLM; Dos Santos Oliveiros Paiva BCB; Lapa PAA
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3601-3611. PubMed ID: 34570257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation.
    Dashevsky BZ; Zhang C; Yan L; Yuan C; Xiong L; Liu Y; Liu H; Kong FS; Pu Y
    Eur J Hybrid Imaging; 2017; 1(1):8. PubMed ID: 29782599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [
    Zhang L; Xu C; Zhang X; Wang J; Jiang H; Chen J; Zhang H
    Eur Radiol; 2023 Mar; 33(3):1757-1768. PubMed ID: 36222865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
    Zhang H; Wroblewski K; Appelbaum D; Pu Y
    Int J Comput Assist Radiol Surg; 2013 Mar; 8(2):181-91. PubMed ID: 22644386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
    Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.
    Newman S; Bucknell N; Bressel M; Tran P; Campbell BA; David S; Haghighi N; Hanna GG; Kok D; MacManus M; Phillips C; Plumridge N; Shaw M; Wirth A; Wheeler G; Ball D; Siva S
    Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):163-171. PubMed ID: 33129655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H; Wroblewski K; Pu Y
    Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.